Back to News
Market Impact: 0.42

Insperity (NSP) Q1 2026 Earnings Transcript

NSPWDAYNFLXNVDAJPM
Corporate EarningsCorporate Guidance & OutlookCompany FundamentalsCapital Returns (Dividends / Buybacks)Artificial IntelligenceTechnology & InnovationM&A & RestructuringEconomic Data

Insperity reported Q1 adjusted EPS of $1.31, down 17% year over year, while adjusted EBITDA rose 1% to $103 million, helped by gross margin recovery and expense control. Management left full-year adjusted EBITDA guidance unchanged at $170 million to $230 million, but cut worksite employee guidance to 303,000-307,000 and lowered adjusted EPS guidance to $1.60-$2.60 due to softer SMB sentiment, higher tax rates, and slower unit growth. The company also highlighted $23 million in dividends, $4 million of share repurchases, and early traction for its HRScale platform, with nearly 6,000 employees committed for onboarding over the next six months.

Analysis

The key read-through is that Insperity is deliberately trading near-term volume for cleaner economics, and the market should stop treating the revenue guide cut as purely demand-driven. The mix shift toward less-profitable client attrition is a hidden positive for near-term margin, but it also means the company is scrubbing out lower-quality growth, which can make reported unit trends look worse before they look better. That sets up a classic earnings-quality improvement story where EBITDA can hold up while the equity multiple stays compressed because investors anchor on shrinking worksite employees. The bigger second-order issue is timing. The new healthcare contract and margin recovery plan appear to push more economics into the back half, so Q2 likely remains the softest point for sentiment, with visible improvement more probable in Q3/Q4 if claims and client mix behave. That creates a favorable setup for investors who can tolerate two quarters of ugly optics: if the company shows even modest stabilization in paid employees while gross profit per employee keeps trending higher, the stock can re-rate quickly because the sell-side is likely underestimating the operating leverage from expense discipline and HRScale deployment. HRScale is the real optionality, but the market may be too focused on near-term implementation drag rather than conversion economics. The platform is not just a product launch; it is a retention defense mechanism for the most valuable accounts and a way to expand addressable account size, which should reduce BPA intensity per dollar of growth over time. If adoption gains traction, the company could transition from a mature PEO with cyclical volume risk to a higher-ARPU hybrid software/services model, and that is the piece the consensus is probably underpricing. Contrarian view: the crowd may be too optimistic on macro stabilization in SMBs and too pessimistic on margin durability. If SMB sentiment keeps deteriorating, HRScale won’t fully offset slower sales in 2026, but the downside is partly cushioned because weaker new sales may actually help mix and margins. The more important risk is that the market gives no credit until HRScale proves it can scale beyond pilot commitments, so the stock could remain range-bound unless management shows sequential improvement in onboarding, retention, and unit growth by late summer.